

## Special Issue

# Cancer Immunotherapy and Vaccination: Mechanistic Insights into Lymphocyte-Mediated Immune Modulation

### Message from the Guest Editor

Cancer remains a major public health and economic issue with an ever-increasing burden. The advancement of cancer vaccines and immunotherapies, including checkpoint inhibitors and oncolytic virotherapy, that are able to amplify the body's immune system against cancer has shown great promise. However, many human cancers fail to respond to these regimens due to the body's own immunosuppressive tumor-promoting mechanisms that represent critical barriers to effective anti-tumor immunotherapies and vaccination. These mechanisms include the presence of immunosuppressive cells, e.g., regulatory T-cells, and dysfunctional effector cells that fail to exert anti-tumor activity in the tumor microenvironment. This Special Issue aims to provide a platform to all scientists working in these fields to discuss the currently known and any new mechanisms underlying the immune modulation induced by any developed or new cancer vaccines and immunotherapeutic approaches, with a focus on the immune responses driven by lymphocytes, including T-cells, B-cells, NK and innate lymphoid cells (ILC).

---

### Guest Editor

Dr. Jianmei Leavenworth  
Heersink School of Medicine, University of Alabama at Birmingham  
(UAB), Birmingham, AL 35233, USA

---

### Deadline for manuscript submissions

closed (31 December 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/105295](https://mdpi.com/si/105295)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).